Melatonin-metabolite changes are not sleep-treatment outcomes
Rather than merely debating compounding categories, regulatory bodies must recognize that without robust oversight and a strict mandate for high-quality clinical evidence, the widespread adoption of these signaling molecules will continue to outpace our clinical understanding of their long-term safety, effectively turning an entire generation of patients into an unregulated experiment
Diseases such as Alzheimers, dementia, sarcopenia, arthritis, Parkinsons, osteoporosis, maculopathy, COPD, and cancer increase with advancing age (Franceschi et al 2018)
Chung KA, Lobb BM, Nutt JG, Horak FB
Clinical studies indicate 1-3% concentrations deliver optimal efficacy for skin remodeling benefits without irritation